Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors

Management of fear of radiation exposure in carers of outpatients treated with iodine-131

(2012) Phillipe J. Calais et al.   ANNALS OF NUCLEAR MEDICINE

Outpatient therapeutic nuclear oncology

(2012) J. Harvey Turner   ANNALS OF NUCLEAR MEDICINE

Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

(2012) Phillip G. Claringbold et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Outpatient 131I-Rituximab Radioimmunotherapy for Non-Hodgkin Lymphoma

(2012) Phillipe J. Calais et al.   CLINICAL NUCLEAR MEDICINE

Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms

(2012) Richard P. Baum et al.   SEMINARS IN NUCLEAR MEDICINE

Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective

(2011) Tatsuya Higashi et al.   ANNALS OF NUCLEAR MEDICINE

Automated Module Radiolabeling of Peptides and Antibodies with Gallium-68, Lutetium-177 and Iodine-131

(2011) Mario De Decker et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

(2011) Jolanta Kunikowska et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Real Cost of Theoretic Risk Avoidance: The Need to Challenge Unsubstantiated Concerns About 131I Therapy

(2011) S. J. Goldsmith   JOURNAL OF NUCLEAR MEDICINE

Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131I: Practice Recommendations of the American Thyroid Association

(2011) The American Thyroid Association Ta Sisson et al.   THYROID

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

(2010) N C Turner et al.   BRITISH JOURNAL OF CANCER

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

(2010) Phillip G. Claringbold et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

(2009) Dik J. Kwekkeboom et al.   NEUROENDOCRINOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY